Youths with achondroplasia who received increasing subcutaneous doses of the new drug vosoritide daily had a 50% faster growth rate on average than at baseline and height improvements were sustained after nearly four years, Australian researchers reported in The New England Journal of Medicine. The findings also showed that vosoritide had mostly mild side effects, didn't adversely affect body proportion and didn't speed up overall bone age, indicating that it may boost final height in adulthood.
Breakthrough drug may benefit children with achondroplasia
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.